Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: Results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

British Journal of Dermatology

Volumn 166, Issue 4, 2012, Pages 853-860

  Bissonnette, R ^a   Poulin, Y ^b   Zhou, Y ^c   Tan, J ^d   Hong, H C ^e   Webster, J ^f   Ip, W ^f   Tang, L ^f   Lyle, M ^f  

^a INNOVADERM RESEARCH   (Canada)

^b Centre de Recherche Dermatologique du Québec Métropolitain   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Windsor Clinical Research Inc   (Canada)

^e Guildford Dermatology Specialists   (Canada)

^f Welichem Biotech Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYL 5 [(E) 2 PHEPHENYLETHENYL]BENZENE 1,3 DIOL; DERMATOLOGICAL AGENT; PLACEBO; UNCLASSIFIED DRUG; WBI 1001;

ABDOMINAL PAIN; ADULT; AGED; APPLICATION SITE IRRITATION; ARTICLE; ATOPIC DERMATITIS; BACKACHE; BODY SURFACE; CELLULITIS; CLINICAL EVALUATION; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; CREAM; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEMALE; FOLLICULITIS; GASTROENTERITIS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NECK PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECZEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; RESORCINOLS; SEVERITY OF ILLNESS INDEX; STILBENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862777041     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10775.x     Document Type: Article

References (15)

1. Katoh N,. Future perspectives in the treatment of atopic dermatitis. J Dermatol 2009; 36: 367-76.
2. Bieber T,. Atopic dermatitis. N Engl J Med 2008; 358: 1483-94.
3. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-7.
4. Wise RD,. A review of atopic dermatitis. Compr Ther 2006; 32: 111-17.
5. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-72.
6. Langley RG, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007; 215 (Suppl. 1): 27-44.
7. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156: 203-21.
8. Bissonnette R, Chen G, Bolduc C, et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol 2010; 146: 446-9.
9. Hanifin JM,. Atopic dermatitis. J Am Acad Dermatol 1982; 6: 1-13.
10. Rajka G, Langeland T,. Grading of the severity of atopic dermatitis. Acta Derm Venereol (Stockh) 1989; 144 (Suppl.): 13-14.
11. Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
12. Rullo VE, Segato A, Kirsh A, et al. Severity scoring of atopic dermatitis: a comparison of two scoring systems. Allergol Immunopathol (Madr) 2008; 36: 205-11.
13. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
14. Fleischer AB Jr, Abramovits W, Breneman D, et al. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatolog Treat 2007; 18: 151-7.
15. Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810-22.